Participants were divided into 4 groups based on serum insulin levels: Q1 (0.71–6.41 μU/mL, n = 698) with a NAFLD prevalence of 27.1%; Q2 (6.44–10.59 μU/mL, n = 693) with a prevalence of 52.5%; Q3 (10.61–17.18 μU/mL, n = 702) with a prevalence of 71.2%; and Q4 (17.20–512.50 μU/mL, n = 698) with a prevalence increasing to 87.5%. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.